Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Levetiracetam (LEV: (S)-α-ethyl-2-oxo-pyrrolidine acetamide) is an
anticonvulsant/antiepileptic drug. The specific aim of this study is to assess the efficacy
of low-dose LEV in reducing hippocampal activity in schizophrenia. The investigators also
hypothesize that LEV will improve neurocognition in participants with schizophrenia.